The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
SPT Labtech, a company that designs and develops automated instrumentation and consumables for life science applications, has expanded its sample management capabilities for the life sciences industry with the recent acquisition of BioMicroLab, a US-based robotics automation provider for life science laboratories. SPT Labtech made the acquisition in February 2021.
BioMicroLab designs and manufactures laboratory automation equipment for biotechnology and scientific research, and its offerings include an extensive range of sample handling and tracking solutions, which complements SPT Labtech's capabilities in modular, automated sample storage systems as well as expands SPT Labtech's product portfolio in the sample management market, SPT Labtech said in a Feb. 15, 2021 press release.
"Over the last 25 years, BioMicroLab has established a well-deserved reputation as a dependable partner for intuitive and reliable benchtop automation. This important investment delivers significant benefits to customers by creating a powerful end-to-end solution to streamline sample management workflows. We are delighted to welcome BioMicroLab to SPT Labtech," said Patrick Bennett, group CEO at SPT Labtech, in the press release.
"SPT Labtech has an impressive track record of harnessing innovation to overcome tough research challenges and deep expertise across a range of life sciences applications. We are confident that customers will benefit from our combined capabilities and look forward to continuing to enable their research success as part of the SPT Labtech team," added David Miller, president of BioMicroLab, in the press release.
Source: SPT Labtech
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.